NCT05355467View on ClinicalTrials.gov

Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 21, 2019

Primary Completion Date

July 13, 2021

Study Completion Date

July 13, 2021

Conditions
Chronic Hepatitis B Infection
Interventions
DRUG

Tenofovir disoproxil fumarate

Ricovir® (tenofovir disoproxil fumarate 300 mg) 1 tablet daily. The overall treatment period is 24 weeks.

OTHER

Historical Data

Historical Data

Trial Locations (1)

40705

Taichung Veterans General Hospital, Taichung

All Listed Sponsors
lead

Mylan (Taiwan) Ltd

INDUSTRY

NCT05355467 - Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum | Biotech Hunter | Biotech Hunter